Pasithea Therapeutics Corp. (KTTA) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Pasithea Therapeutics Corp. (KTTA).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $0.671

Daily Change: -$0.014 / 2.09%

Daily Range: $0.671 - $0.705

Market Cap: $5,210,506

Daily Volume: 45,204

Performance Metrics

1 Week: -3.46%

1 Month: 0.16%

3 Months: -38.05%

6 Months: -74.45%

1 Year: -88.80%

YTD: -77.78%

Company Details

Employees: 4

Sector: Health technology

Industry: Pharmaceuticals: major

Country:

Details

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Selected stocks

Crescent Capital BDC, Inc. (CCAP)

Voya Global Advantage and Premium Opportunity Fund (IGA)

Crescent Capital BDC, Inc. 5.00% Notes due 2026 (FCRX)